van Dijk, Hanneke
deBeus, Roger
Kerson, Cynthia
Roley-Roberts, Michelle E.
Monastra, Vincent J.
Arnold, L. Eugene
Pan, Xueliang
Arns, Martijn
Funding for this research was provided by:
NIMH (R01 MH 100144)
Article History
First Online: 20 May 2020
Compliance with Ethical Standards
:
: Dr. Roger deBeus has received research funding from the Commonwealth Health Research Board of Virginia, Riverside Healthcare Foundation, VuBay Foundation, Edwin Joseph Foundation, and NIMH. Dr. Cynthia Kerson is President of Applied Psychophysiology Education (APEd). Dr. Vince Monastra has received royalty payments from the Biofeedback Federation of Europe for the development of the Monastra-Lubar ADHD Assessment Suite. Dr. L. Eugene Arnold has received research funding from Curemark, Forest, Lilly, Neuropharm, Novartis, Noven, Shire, Supernus, Roche, and YoungLiving (as well as NIH and Autism Speaks), has consulted with Gowlings, Neuropharm, Organon, Pfizer, Sigma Tau, Shire, Tris Pharma, and Waypoint, and been on advisory boards for Arbor, Ironshore, Novartis, Noven, Otsuka, Pfizer, Roche, Seaside Therapeutics, Sigma Tau, Shire. Martijn Arns is unpaid research director of the Brainclinics Foundation, a minority shareholder in neuroCare Group (Munich, Germany), and a co-inventor on 4 patent applications (A61B5/0402; US2007/0299323, A1; WO2010/139361 A1; WO2017/099603 A1) related to EEG, neuromodulation and psychophysiology, but does not own these or receives any proceeds related to these patents; Research Institute Brainclinics received research funding from Brain Resource (Sydney, Australia), UrgoTech and neuroCare Group (Munich, Germany), and equipment support from Deymed, neuroConn and Magventure unrelated to this manuscript. Hanneke van Dijk, Michelle Roley-Roberts and Xueliang Pan declare that they have no conflict of interest.